Articles tagged with Pancreatic Cancer
The study recommends prioritizing pancreatic surgery for non-COVID-19 patients and informing them of additional risks. Surgeons also emphasize the need for protective features in operating rooms and proper triage for hospital resources during the pandemic.
An exploratory study found that metformin combined with rapamycin was well-tolerated in patients with stable or responding metastatic pancreatic ductal adenocarcinoma (mPDA) after 6 months of chemotherapy. The combination was associated with exceptionally long survival rates and improved disease stability.
A key cell signaling pathway drives cancer-associated muscle loss, and targeting this pathway with a drug like GKT137831 could prevent cachexia. The study found that restoring SIRT1 levels can prevent muscle degeneration and extend the life of mice with pancreatic cancer
The UCLA Jonsson Comprehensive Cancer Center has been awarded a $5.75 million grant to study the role of obesity in the development of pancreatic cancer. The research aims to understand how inflammation from obesity influences tumor formation and develop prevention strategies for high-risk individuals.
Researchers discovered how pancreatic cells lose their identity and recruit nearby cells to help them grow and invade tissues. Transcription factors ZBED2 and p63 play a key role in this process, leading to aggressive cancer behavior.
Fibroblasts from distinct pancreatic diseases exhibit distinct genetic profiles and gene expression patterns, highlighting the importance of using disease-specific fibroblasts for research. The study also identifies a potential biomarker for distinguishing between pancreatic cancer and chronic pancreatitis.
Researchers at City of Hope have identified a novel microRNA biomarker that can detect lymph node metastases in pancreatic ductal adenocarcinoma, which makes up about 80% of all pancreatic cancer cases. The test has an accuracy level of 78% and could lead to more personalized treatment strategies for patients.
A CNIO-led European study has confirmed that diabetes type 3c is an early manifestation of pancreatic cancer, allowing for earlier diagnosis and treatment. The study found that pancreatic cancer is the cause of the development of diabetes type 3c in 26% of cases.
Researchers at University of Pennsylvania activate G protein-coupled estrogen receptor (GPER) in human and mouse pancreatic cancer models, inhibiting growth and making tumors more sensitive to immunotherapy. This approach may improve efficacy of existing treatments in a type where PD-1 inhibitors have been ineffective.
Researchers at Houston Methodist developed a clinically-applicable mathematical model to predict patient outcomes in cancer immunotherapy. The model uses CT-scan imaging data to identify patient-specific indicators of therapeutic response, correlating with anti-tumor immune state and tumor kill rates.
Researchers found that pancreatic cancer cells use autophagy to degrade MHC-I proteins, making them resistant to immunotherapies. Blocking autophagy or using drugs like chloroquine enhances MHC-I expression on the surface of cancer cells, increasing their susceptibility to immunotherapy.
Researchers at Salk Institute discover formation of tuft cells during pancreatitis, which secrete IL-25 to promote immune response. The finding may lead to development of new treatments for pancreatitis and pancreatic cancer.
Researchers developed a liquid biopsy blood test that detects pancreatic cancer earlier and more accurately than existing biomarkers. The test outperforms imaging alone in staging disease, offering hope for patients with limited treatment options.
Regular aspirin use is linked to reduced risk of bowel, oesophageal, stomach, and pancreatic cancers. Aspirin doses between 75-500mg/day are associated with increased cancer risk reduction.
Scientists at Sanford Burnham Prebys have found a new way to kill pancreatic cancer cells by disrupting their pH equilibrium. Suppressing NHE7 lowers the cell's cytoplasmic pH, triggering cell death in both human and mouse tumors. This approach could provide a new therapeutic avenue for treating pancreatic cancer.
A new study found that starving pancreatic cancer cells of cysteine leads to their death by ferroptosis, a form of programmed cell death. The compound was shown to be effective in mice with pancreatic cancer and may lead to new treatments for this deadly disease.
A new study found that a novel peptide antagonist given in combination with a PD-1 inhibitor is safe and well-tolerated in patients with advanced, refractory pancreatic and rectal cancer. The highest dose tested resulted in no adverse events leading to the recommendation for use in future trials.
The Oncotarget review explores the use of biomarkers, CA19-9, gemcitabine-abraxane, FOLFIRINOX, and other treatments to identify patients who benefit most from therapy in pancreatic cancer. Further studies are needed to better understand pancreatic cancer biology and improve prognosis.
Researchers developed a microRNA-based signature that predicts local-regional failure and overall survival in patients with pancreatic cancer. The four-miRNA risk score provides prognostic information for clinical outcomes after surgical resection.
Researchers developed a new concept of resectability and identified objective pre-operative prognostic factors to predict long-term survival in pancreatic cancer patients. The study's nomogram can estimate patient outcomes before surgery, regardless of local anatomic features.
The Pancreatic Cancer Collective has awarded $16 million to four research teams pursuing preclinical work and clinical trials for new pancreatic cancer treatments. These breakthroughs aim to improve the five-year survival rate of 9%.
A study published in Journal for ImmunoTherapy of Cancer found that introducing bone marrow cells with a specific gene deletion can induce an immune response against prostate and pancreatic cancer cells. The technique, known as adoptive cell therapy, uses patients' own marrow cells to target cancer.
Results from 46 patients who received targeted therapies alongside standard chemotherapy showed a 31-month average survival compared to 18 months for those without molecular changes. Targeted therapy has already improved survival for many forms of cancer and could be a game-changer for pancreatic cancer patients with specific alterations.
Researchers have found a promising candidate to advance pancreatic cancer immunotherapy: innate lymphoid cells (ILCs), particularly ILC2s. Activating ILC2s with interleukin 33 (IL-33) enhances antitumor activity, which may complement existing checkpoint inhibitors.
Researchers developed a pancreatic tumor model that condenses cancer development to just two weeks, allowing them to observe trends in cell growth and invasion. The study found that cancer cells from different mutations become more invasive when they grow together, which challenges the current understanding of disease progression.
Scientists have identified a peptide from the foot-and-mouth-disease virus that targets a protein on pancreatic cancer cells, allowing for highly potent drug delivery and complete tumour killing in mice. The research offers a promising new approach to treating pancreatic cancer with limited side effects.
A team at Tohoku University discovered that BACH1 facilitates pancreatic cancer spread by reducing cell-to-cell adhesion. Silencing or overexpressing BACH1 in pancreatic cancer cells reduced metastasis and improved survival rates.
Research found that high CO2 levels drive the aggressiveness of pancreatic tumor cells and their resistance to treatment. Increasing CO2 levels in cell cultures also showed increased growth and aggression, while common chemotherapeutic agents and radiation therapy were less effective against high-CO2-cultured cells.
UK scientists have discovered a potential new treatment strategy for pancreatic cancer by targeting energy production in cells, leading to an irreversible build-up of calcium and cell death. The approach involves inhibiting a specific enzyme called PKM2, which fuels calcium pumps on the cell surface.
Researchers identified five distinct subtypes of advanced pancreatic cancer with unique molecular properties that can be targeted with novel treatments. The study's findings may lead to improved clinical outcomes and personalized treatment decisions for patients with the deadly disease.
Researchers found that pancreatic tumor cells secrete interleukin-1β (IL-1β) to reduce anti-cancer immune responses, promoting PDA tumor growth. Blocking IL-1β with an antibody treatment doubled T cell infiltration and increased PD-1 blockade efficacy by 40%.
Researchers have developed drug-like molecules from a tropical flower that kill pancreatic cancer cells, offering a potential new route for treatment. The findings suggest these 'anti-austerity' agents could remove the ability of cancer cells to tolerate starvation conditions, leading to cell death.
Pancreatic cancer cells use a process called macropinocytosis to engulf nutrients, which are then broken down into building blocks for cell growth. The study identified key molecular steps involved in boosting this process, including the activation of protein kinase A and v-ATPase.
Researchers at The Ohio State University Wexner Medical Center have developed a new 'virtual biopsy' method that accurately diagnoses precancerous pancreatic cysts with unprecedented accuracy. This diagnostic tool allows doctors to eliminate precancerous cysts and potentially save lives by identifying them early.
Researchers at American Friends of Tel Aviv University have developed a new treatment that triggers the self-destruction of pancreatic cancer cells. The innovative therapy has shown promising results in its early stages, providing hope for patients with pancreatic cancer.
Researchers from Queen Mary University of London and Zhengzhou University have developed a personalised vaccine system that can delay the onset of pancreatic cancer. The system was tested in mice, where it doubled their survival time compared to those without the vaccine.
Researchers at the University of South Australia are developing a new radioimmunotherapy agent to target and kill pancreatic cancer cells, potentially minimizing side effects. The treatment uses alpha particles to deposit energy inside cancer cells while leaving healthy tissue intact.
Researchers developed a new two-subtype system to classify pancreatic cancer tumors based on treatment response data from clinical trials. The study found that patients with basal-like tumors showed poor responses to common therapies and worse survival outcomes.
Scientists at Sanford Burnham Prebys Medical Discovery Institute identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice, supporting the immediate evaluation of the drugs in a clinical trial. The study provides rationale for an immediate clinical trial evaluating the 2 therapies
A study published in Nature Cell Biology has identified a protein called CD9 that drives growth of pancreatic cancer and could be a target for new treatments. The researchers found that CD9 is present on the surface of cancer stem cells, which are a driving force behind cancer growth.
Researchers at Osaka University have developed a new radiation therapy method that targets pancreatic cancer cells directly, reducing side effects. The treatment uses a radioactive molecule that binds to specific proteins on stroma cells surrounding tumors, delivering high-energy doses of radiation to cancer tissue.
Researchers at Washington University and USF Health developed a peptide-based nanoparticle that delivers siRNA to suppress KRAS-driven cancer growth without adverse effects. The nanoparticles effectively target tumor cells, reducing tumor cell death and slowing cancer growth.
A major study across 195 countries found that global death rates for pancreatic cancer and incidence rates for colorectal cancer increased by 10% between 1990 and 2017. The study also reported significant increases in cases of inflammatory bowel disease (IBD) and a rise in obesity-related risk factors for pancreatic cancer.
Researchers at Georgetown University Medical Center developed a virtual review method that reduces the time needed to assess a cancer patient's tumor profile and suitability for clinical trials from 14 to 4 days. The method also increased the number of cases that could be assessed, with over 2,000 clinical trials evaluated.
A new study published in Nature found that a single genetic mutation in the SF3B1 gene is associated with an increased risk of developing various types of cancer. The researchers discovered that this mutation leads to the production of abnormal RNA molecules, including noncoding DNA sequences that disrupt the genetic message.
A new treatment combination using stereotactic body radiotherapy and interleukin-12 has been shown to cure pancreatic cancer in mice by activating T-cells to attack cancer cells. The treatment also destroys pancreatic cells that have spread to the liver, a common site for metastatic disease.
A research team has identified a protein called Meflin in cancer-suppressing cells surrounding pancreatic cancer. Increasing Meflin levels can restrain cancer progression and may lead to new therapies against the disease.
A phase 1b/2 clinical trial found that adding cisplatin to a standard-of-care regimen resulted in 71% tumor shrinkage and increased survival beyond one year. The treatment showed encouraging results, with 64% of patients alive after one year and 40% alive after two years.
Certain fungi can expand their population over a thousand-fold, encouraging pancreatic cancer growth, according to a new study. The study found that treating mice with an antifungal drug reduced PDA tumor weight by 20-40 percent.
Researchers found PML dysfunction due to altered protein modification, specifically sumoylation, enables pancreatic tumor resistance to chemotherapeutic treatment. High PML expression and sumoylation are associated with better survival rates in patients.
Researchers have discovered a key mechanism behind pancreatic cancer's aggressive growth, which may help explain why promising drugs work and when they won't. The finding identifies a weakness in the cancer cells' metabolism that could be exploited to improve treatment outcomes.
A urine test that measures specific proteins found in urine can detect early-stage pancreatic cancer with nearly 95% accuracy. The UroPanc clinical study aims to validate this biomarker in a clinical setting, with the potential to develop a standardized urine test for clinicians to use as a diagnostic aid.
Researchers at Mayo Clinic discovered that inhibiting GSK-3 enzyme sensitizes pancreatic cancer cells to gemcitabine, a commonly used chemotherapy. This new approach may overcome resistance to chemotherapy and improve treatment outcomes for patients with pancreatic cancer.
Researchers at Johns Hopkins Medicine have discovered that the compound 4-HAP can reduce metastatic tumor formation in mouse models of human pancreatic cancer. By stiffening cells and overwhelming their ability to invade nearby tissue, 4-HAP may help halt the progression of disease-like behavior in pancreatic cancer cells.
Researchers at MD Anderson Cancer Center confirm ubiquitin specific protease 21 (UPS21) as a frequently amplified gene in pancreatic ductal adenocarcinoma (PDAC), a form of pancreatic cancer. Depletion of UPS21 impairs tumor growth, promoting malignant transformation and cancer cell stemness.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline recommending the use of radiation therapy in pre-surgical, post-surgical, definitive and palliative settings. The guideline emphasizes a patient-centered approach integrating patients' values and preferences into treatment decisions.
A new study reveals pancreatic cancer cells invade and destroy nearby blood vessels, replacing them with tumor-lined structures. The process is driven by the interaction between the protein receptor ALK7 and the protein Activin, pointing to a possible target for future treatments.
A team of researchers at Georgetown University Medical Center has identified a chain of molecules critical for pancreatic ductal adenocarcinoma (PDAC) growth and survival. Inhibiting this 'Yap' biological network may effectively regress early-stage PDAC, and pairing it with other drugs could halt more advanced stage tumors.
Researchers found that abemaciclib, a chemotherapeutic agent effective in breast cancer, has synergy when combined with HuR and YAP1 inhibitors to inhibit cell growth. The study suggests new targets for improving the efficacy of this drug and overcoming drug resistance in pancreatic cancer.
Scientists at Huntsman Cancer Institute have discovered a way for cells to override genetic changes, potentially leading to more effective pancreatic cancer treatment. The study found that introducing PTF1A into normal cells prevented the formation of cancer cells and even reversed early-stage cancer cells back to healthy pancreas cells.